EUVIMEDEUVIMED entdecken
MetaanalyseSystematische ÜbersichtOpen Access · CC BY 4.0

Baseline Ejection Fraction as a Modifier of Beta‐Blocker Therapeutic Effects in Post‐Acute Coronary Syndrome Patients With Non‐Reduced Ejection Fraction: A Systematic Review and Meta‐Analysis

Seyed Alireza Mirhosseini iD, Seyed Amir Sadrzadeh, Davood Semirani-Nezhad, Erta Rajabi iD, Hanieh Mohammadi, Alireza Shaabanpoor Haghighi, Mohammad Amin Jamali, Reza Moshfeghinia, Maryam Ranjbar, Pouria Azami iD, Rahul Gupta, Wilbert S Aronow und 1 weitere

Cardiovascular Therapeutics · 2026-01 · 2026 (1)

DOI: 10.1155/cdr/2988999 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift Cardiovascular Therapeutics, online erschienen am 17.06.2026. Verfasst von Seyed Alireza Mirhosseini und 12 weiteren Autor:innen. Beteiligte Einrichtung: Cardiovascular Research Center, Shiraz University of Medical Sciences, Shiraz, Iran, sums.ac.ir. Hauptthemen laut MEDLINE: Acute Coronary Syndrome, Adrenergic beta-Antagonists, Stroke Volume, Ventricular Function, Left. Die Arbeit nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Beta‐blockers are regarded as one of the primary treatment options for acute coronary syndrome (ACS) patients with reduced left ventricular ejection fraction (LVEF). However, there is ongoing debate about their therapeutic efficacy in patients with non‐reduced LVEF (≥ 40%).

Objective

To determine the impact of long‐term beta‐blocker administration on major adverse cardiovascular events (MACE) in ACS patients with LVEF ≥ 40 % .

Methods

A thorough literature search across four databases was conducted to identify eligible studies comparing beta‐blocker therapy with placebo or no medication in addition to standard ACS pharmacotherapy. The outcomes of interest included all‐cause mortality and MACE (comprising cardiovascular mortality, recurrent myocardial infarction [Re‐MI], stroke, rehospitalization for heart failure, and revascularization). Based on LVEF values, patients were divided into three groups: (1) LVEF > 40 % , (2) 40 % < LVEF < 50 % , and (3) LVEF ≥ 50 % , and the random‐effects meta‐analysis estimated the risk ratios (RRs), hazard ratios (HRs), and 95% confidence intervals (CIs).

Results

Five randomized controlled trials (RCTs) and 19 observational studies met the inclusion criteria. Within the RCTs, beta‐blocker use was associated with a non‐significant 6% reduction in MACE (RR = 0.94, 95 % CI = 0.87–1.02, I 2 = 19.1 % ). The pooled analyses of observational studies showed no significant overall impact of beta‐blocker use on endpoint outcomes. Subgroup analyses revealed a reduction in MACE (HR = 0.75, 95 % CI = 0.59–0.95, I 2 = 0 % ) and Re‐MI (HR = 0.45, 95 % CI = 0.23–0.89) in patients with LVEF 40%–49%; however, these findings were derived primarily from observational data. Patients with LVEF ≥ 50 % did not appear to benefit from long‐term beta‐blocker use.

Conclusion

Long‐term beta‐blocker use did not show a significant benefit in patients with preserved ejection fraction (LVEF ≥ 50 % ). Observational data suggested a possible reduction in MACE and Re‐MI in the LVEF 40%–49% subgroup; however, this finding requires confirmation in dedicated RCTs. Future larger RCTs are needed to clarify the role of beta‐blockers in this borderline population.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Acute Coronary SyndromeAdrenergic beta-AntagonistsStroke VolumeVentricular Function, LeftAgedFemaleHumansMaleMiddle AgedMyocardial InfarctionOdds RatioRandomized Controlled Trials as TopicRecurrenceRisk FactorsTime FactorsTreatment Outcome

Stichwörter der Autor:innen

acute coronary syndromebeta-blockermortalitymyocardial infarctionpreserved ejection fraction

Substanzen

Adrenergic beta-Antagonists

Autor:innen und Institutionen

  • Cardiovascular Research Center, Shiraz University of Medical Sciences, Shiraz, Iran, sums.ac.ir.
  • Department of Cardiovascular Medicine, TAHA Clinical Trial Group, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran, sums.ac.ir.
  • Student Research Committee, Shiraz University of Medical Sciences, Shiraz, Iran, sums.ac.ir.
  • Tehran Heart Center, Cardiovascular Diseases Research Institute, Tehran University of Medical Sciences, Tehran, Iran, tums.ac.ir.
  • Faculty of Medicine, Tehran University of Medical Sciences, Tehran, Iran, tums.ac.ir.
  • MD-MPH Department, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran, sums.ac.ir.

ORCID-Profile: Seyed Alireza Mirhosseini, Erta Rajabi, Pouria Azami, Armin Attar

Zitieren

APA

Mirhosseini, S. A., Sadrzadeh, S. A., Semirani-Nezhad, D., Rajabi, E., Mohammadi, H., Shaabanpoor Haghighi, A., Jamali, M. A., Moshfeghinia, R., Ranjbar, M., Azami, P., Gupta, R., Aronow, W. S., & Attar, A. (2026). Baseline Ejection Fraction as a Modifier of Beta‐Blocker Therapeutic Effects in Post‐Acute Coronary Syndrome Patients With Non‐Reduced Ejection Fraction: A Systematic Review and Meta‐Analysis. Cardiovascular Therapeutics, 2026(1). https://doi.org/10.1155/cdr/2988999

Vancouver

Mirhosseini SA, Sadrzadeh SA, Semirani-Nezhad D, Rajabi E, Mohammadi H, Shaabanpoor Haghighi A, et al. Baseline Ejection Fraction as a Modifier of Beta‐Blocker Therapeutic Effects in Post‐Acute Coronary Syndrome Patients With Non‐Reduced Ejection Fraction: A Systematic Review and Meta‐Analysis. Cardiovascular Therapeutics. 2026;2026(1). doi:10.1155/cdr/2988999

BibTeX
@article{Mirhosseini2026,
  author = {Mirhosseini, Seyed Alireza and Sadrzadeh, Seyed Amir and Semirani-Nezhad, Davood and Rajabi, Erta and Mohammadi, Hanieh and Shaabanpoor Haghighi, Alireza and Jamali, Mohammad Amin and Moshfeghinia, Reza and Ranjbar, Maryam and Azami, Pouria and Gupta, Rahul and Aronow, Wilbert S and Attar, Armin},
  title = {Baseline Ejection Fraction as a Modifier of Beta‐Blocker Therapeutic Effects in Post‐Acute Coronary Syndrome Patients With Non‐Reduced Ejection Fraction: A Systematic Review and Meta‐Analysis},
  journal = {Cardiovascular Therapeutics},
  year = {2026},
  volume = {2026},
  number = {1},
  doi = {10.1155/cdr/2988999}
}
Kostenlos starten →